Pollard discussed progress in the late-stage trials as Oxford released a study based on earlier research that found the vaccine was well tolerated and produced a strong immune response in people over 70.
CoronaVac and four other experimental vaccines developed in China are undergoing late-stage trials to determine their effectiveness in preventing Covid-19.
The GMR Group, which operates Delhi and Hyderabad airports, says the air cargo units of both these places are getting ready to "play a pivotal role in the distribution of vaccines through state of the art time and temperature-sensitive distribution system" with cool chambers ranging from +25°C to -20°C.
Many other airports and airlines are also learnt to be preparing for vaccine transportation - possibly the largest ever air cargo opportunity so far; comments from them were awaited. "The next step will be to see if this translates into protection from the disease itself", he added.More news: NASA Attempts First-Ever Mission To Collect Asteroid Sample
According to the researchers, volunteers in the trial demonstrated similar immune responses across all three age groups (18-55, 56-69, and 70 and over).
The study's findings, which looked only at data from the phase 2 trial, are important because older adults often have a lessened immune response and are more susceptible to infections, explained the study's lead author, Andrew Pollard.
"As a result, it is crucial that COVID-19 vaccines are tested in this group who are also a priority group for immunization", he said in a news release from the journal The Lancet. T-cell response occurred within 14 days of the first dose of vaccination, and antibody response occurred within 28 days of the booster dose of vaccination.
"The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults".More news: Canada, Britain strike new trade, beating Brexit, incorporating expiring EU pact
Adverse reactions were mild - injection-site pain and tenderness, fatigue, headache, feverishness and muscle pain - but more common than seen with the control vaccine. Moderna's vaccine can last for a month in a normal fridge or six months if stored at minus 20 Celsius.
On Monday, an EU official involved in the talks said the European Commission wanted to reach a deal with Moderna for the supply of millions of doses of its vaccine candidate for a price below $25 per dose.
Forty million doses of that vaccine have been bought by the United Kingdom, with rollout potentially starting in early December if the jab is given the green light by regulators.More news: Britain hopes Christmas can be saved as COVID cases flatten